Pirtobrutinib: A New Hope for patients with BTK-inhibitor refractory lymphoproliferative disorders.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2023020240
Abstract: Patients with lymphoproliferative disorders such as CLL and Mantle Cell Lymphoma (MCL) who are resistant to covalent BTK inhibitors (cBTKi), especially if also venetoclax-refractory, have an unmet therapeutic need. Pirtobrutinib, a non-covalent BTK inhibitor, achieves… read more here.
Keywords: pirtobrutinib new; btk inhibitor; refractory; lymphoproliferative disorders ... See more keywords